Get started

NVAX

NVAX, is prepping for a turnaround ERA. Massive Growth Prospect!NVAX surged an impressive 29.4% last trading day with significant volume. Net positive volume increased massively from 6.33M to 28.12M for a 344% increase. These extraordinary numbers should be telling of what's to come in the mid to long term. Buyers are back in the scene, positioning at the current price range in anticipation of growth prospect both in technical and fundamental aspect. On our monthly data, some big shifts are happening. On histogram, the stock recorded its third straight shifted lines -- these lines came out after 3.5 years of waiting. Similarly, a fresh bubble up volume re-appeared after a series of descend over the years. This is giving us a lowkey clue already of the intended direction. It is now sitting a 1.0 FIB level, this is beyond bargain / discount already. The stock is hovering around a 4-year longstanding strong support. Expect some upside price valuation to materialize in the next coming weeks. All these 'shifts' are conveying a turnaround prospect for NVAX. Spotted at 9.0 TAYOR. Safeguard capital always
NASDAQ:NVAXLong
by JSAL
11
MRNA Taking Profit, Watching for a add LONG after a pullback.MRNA has been on fire since the earnings beat 4 weeks ago and has added 60% to its market cap in the past three months. It compares well with NVAX which as a prior penny stock has more volatility and upside potential. In general vaccine stocks are performing well as COVID RSV and influenza vaccines are active in research are Viral Hepatitis vaccine enhancements and the drive for an HIV vaccine. MRNA is strong and perhaps becoming overbought. The mass index indicator has topped and maybe falling to the trigger line. I will take a one- third partial off my position here and wait for a pullback with reversal to add back into the position at a lower price. The tandem of MRNA and NVAX has been very profitable for me. Careful in trade management will help me keep it that way.
NASDAQ:MRNALong
by AwesomeAvani
NVAX pushed to bottom of its channel LONGNVAX powered off its earnings and a news catalyst and is overdue now for a correction. While in an ascending channel NVAX is now at the bottom of the channel perhaps due to the general market moves this week. From here it can move up in the channel or breakdown and fall into a significant correction from the uptrend since May 10th. I am bullish on NVAX and have a prior perspective of an insider. I have realized profit six figures from my call options for January 2025 and have a large number remaining in the trade. At this juncture, I will watch for NVAX to move up in the channel and take a trade of shares and some call options for 15.00 expiring in June 2025 to take advantage of long term capital gains on the options. The FDA is currently reviewing some COVID vaccine data which is particularly relevant to NVAX. The volume profile has a shelf at 14.25 which will be my stop loss on the shares. The options will have a 20% stop loss. Considering the level from which NVAX has fallen over a period of some period there is great potential in my opinion.
NASDAQ:NVAXLong
by AwesomeAvani
2
Sanofi Set to Take a 4.9% Stake in Novavax for $70 MillionShah Capital has announced the withdrawal of its campaign against the re-election of three directors on Novavax's board following the COVID-19 vaccine maker's licensing deal with Sanofi. The deal, signed on May 10, entails Sanofi taking a 4.9% stake in Novavax for $70 million at a substantial valuation, including an upfront cash payment of $500 million and future payments contingent on specific milestones and royalties. This move comes after Novavax ( NASDAQ:NVAX ) struggled to bring its protein-based vaccine to the market in a timely manner. Furthermore, the company has removed a warning notice from February last year, which cast doubt on its ability to continue operations, signaling increased stability after the deal with Sanofi. Shah Capital, which holds approximately 7.8% stake in Novavax ( NASDAQ:NVAX ),said that the Sanofi agreement represents a "long-awaited step in the right direction." Despite the withdrawal of its campaign, the fund continues to assert that Novavax ( NASDAQ:NVAX ) would benefit from the addition of a stockholder representative on its board. Novavax ( NASDAQ:NVAX ) has reaffirmed its commitment to driving long-term value for all shareholders and has welcomed the decision by Shah Capital to end its campaign, deeming it as the right choice for shareholders and the company. Moreover, Shah Capital remains vigilant, stating its belief that significant additional value remains to be unlocked at Novavax ( NASDAQ:NVAX ). Technical Outlook The Maryland-based biotech company's stock rose approximately 8.53% to $14.21 in premarket trading, marking an almost threefold increase in value this year. Novavax ( NASDAQ:NVAX ) stock has a Relative Strength Index (RSI) of 79.87 which is quite overbought with the asset trying to maintain the new Resistance Level reached by it. Additionally, as of April 30, the stock's short interest stood at 32% of publicly available shares, according to analytical Data firm LSEG data.
NASDAQ:NVAXLong
by DEXWireNews
Novavax Surge Over 130% On $1.4 Bln Covid Shot Deal with SanofiNovavax shares ( NASDAQ:NVAX ) surged over 130% after a $1.4 billion deal with Sanofi was announced to commercialize its Covid vaccine and develop a new combination shot for protecting against the flu and Covid. The biotech firm announced a licensing agreement with Sanofi to sell Novavax’s Covid vaccine worldwide, with Sanofi paying Novavax $500 million upfront and future payments up to $700 million based on other milestones, in addition to royalties. Sanofi will receive a sole license to develop and commercialize a combination flu and Covid vaccine containing Novavax’s Covid shot and Sanofi’s flu shot. Novavax ( NASDAQ:NVAX ) is also entitled to launch and sales milestones of up to $200 million for any vaccine developed by Sanofi as part of the deal. The company expects to launch a late-stage trial of its own combination vaccine targeting Covid and the flu and a stand-alone flu shot later this year. The licensing agreement will likely lift Novavax’s “going concern” warning issued last year, after the company said “substantial doubt exists” to continue operating. A significant uptick for Novavax ( NASDAQ:NVAX ) shares follows yearslong financial woes for the biotech firm. The company cut its 2024 sales forecast in its first-quarter review, decreasing projections from between $800 million and $1 billion to $400 million to $600 million. Novavax ( NASDAQ:NVAX ) also reported a first-quarter net loss of $148 million, compared with a net loss of $294 million during the same period last year. As part of the deal, Sanofi is also taking a less than 5% equity stake in Novavax, and Novavax ( NASDAQ:NVAX ) will receive royalty payments for future sales of its COVID-19 vaccine and the future combination COVID-19 and flu vaccine. The deal will allow Novavax to lift its “going concern” warning, which was issued in early 2023 over concerns that it may not be able to financially survive as demand for COVID-19 vaccines waned. Alongside the Sanofi deal, Novavax ( NASDAQ:NVAX ) also reported first-quarter results that missed analyst estimates. Novavax ( NASDAQ:NVAX ) reported revenue for the first quarter of $93.9 million, shy of the $101.3 million analysts expected, and posted a loss of $147.6 million, or $1.05 per share, wider than the loss of $127.4 million, or 90 cents per share, that analysts projected. For the full fiscal year, Novavax ( NASDAQ:NVAX ) lowered its projected revenue to $400 million to $600 million, down from the previous range of $800 million to $1 billion. However, the estimated $570 million the company expects to receive from Sanofi this year pushed its combined revenue and payments projections higher, to $970 million to $1.17 billion. Technical Outlook Novavax ( NASDAQ:NVAX ) is up 98% as of the time of writing, trading above the 200-day Moving Average (MA). The stock has a Relative Strength Index (RSI) of 86.66 which is clearly in an overbought territory. The daily price charts depict an upside or upward gap that occurred as a result of the impending deal.
NASDAQ:NVAXLong
by DEXWireNews
1
XBI the ETF for Biotechnology LONGBiotechnology is expected to be a hot subsector this year as healthcare recovered further from the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend with XBI pivoting to bullish back in early November. I add long positions when I see a dip on the 3-4hr chart. My targets are the fib retracement expectation at 116 confluent with the first upper VWAP band line and then the 135-138 zone underneath the second upper line shown in thin red on the chart. This ETF smooths out the volatility characteristic of some of the smaller biotechnology firms making it safer albeit with lesser rewards expectations. Positions in NVAX and MRNA are having a good start to the week and will reflect in a small way in this ETF which has broad constituent stocks within its portfolio.
AMEX:XBILong
by AwesomeAvani
1
Novavax Sees 2024 Sales Flat to Lower, Plummeting By 26.4%In a quest to reclaim lost ground and assert its presence in the competitive COVID-19 vaccine market, Novavax (NASDAQ: NASDAQ:NVAX ) charts a strategic course aimed at improving commercial performance and gaining market share from industry giants Pfizer (PFE.N) and Moderna (MRNA.O). Despite facing headwinds and a larger-than-expected fourth-quarter loss, Novavax ( NASDAQ:NVAX ) remains undeterred in its pursuit of market dominance. Chief Executive John Jacobs acknowledges the company's disappointing performance during the recent vaccination campaign, attributing it to delayed market entry and logistical challenges. However, Jacobs remains resolute in his commitment to enhancing Novavax's competitive positioning and expanding its footprint in the burgeoning vaccine landscape. A key focal point of Novavax's ( NASDAQ:NVAX ) strategy is the pursuit of pre-filled syringes, a format favored by consumers and healthcare providers alike for its convenience and ease of use. Jacobs emphasizes the importance of targeted sales efforts and broad retail availability to drive uptake and accelerate market penetration. Despite near-term revenue challenges, Novavax ( NASDAQ:NVAX ) remains optimistic about its long-term prospects, projecting revenue for 2024 in the range of $800 million to $1 billion. The company's commitment to cost containment and operational efficiency underscores its determination to navigate uncertainties and drive sustainable growth in the years ahead. Novavax's ( NASDAQ:NVAX ) journey has been marked by highs and lows, from soaring market valuations to regulatory hurdles and manufacturing setbacks. However, the company's resilience and adaptability position it well to overcome obstacles and emerge as a formidable player in the global fight against COVID-19. While challenges persist, including lingering doubts about the company's financial viability, Novavax remains focused on execution and delivering value to stakeholders. Jacobs's emphasis on operational improvements and leaner processes reflects a renewed commitment to efficiency and effectiveness in the commercial market. As Novavax ( NASDAQ:NVAX ) embarks on this pivotal phase of its journey, investors and industry observers await eagerly to witness the company's ability to translate strategy into tangible results. With determination, perseverance, and a renewed sense of purpose, Novavax ( NASDAQ:NVAX ) seeks to redefine its narrative and carve out a prominent place in the annals of vaccine innovation.
NASDAQ:NVAX
by DEXWireNews
NVAX Bullish Breakout After Settlement of Gavi DisputeNVAX Technical Analysis NVAX has been showing some solid bullishness since settling the Gavi dispute. NVAX is pumping out of the buy zone, and there has been a bullish breakout above the light blue resistance line. The key price target ahead is the green resistance line ($6.36), a yellow resistance zone ($8.20 to $8.46), and a red resistance line ($10.23). I have $3.54 to $3.93 as my new buy zone. I think there are likely to be more buy opportunities around there. For now the price is bullish and trending up. Novavax Reaches Settlement With Gavi, Paving The Way Forward In a significant development announced on February 22, Novavax, a key player in the COVID-19 vaccine market, has reached a settlement with Gavi, the Vaccine Alliance, resolving a contentious dispute over unfulfilled vaccine orders. This settlement marks a critical juncture for Novavax, alleviating financial uncertainties and setting the stage for future growth and collaborations. The Dispute Resolution Novavax has committed to repaying Gavi a minimum of $475 million, either in cash or through vaccine supplies, by the end of 2028. This agreement comes as a resolution to a conflict stemming from Novavax’s inability to deliver on a contract for up to 350 million doses of its COVID-19 vaccine, despite Gavi’s advance payment of $700 million in 2021 and 2022. Impact On Novavax The announcement led to a significant surge in Novavax’s stock price, which climbed by 23.2% to $4.91 following the news. This is a noteworthy rebound for the company, whose stock had previously plummeted by nearly 60% amid concerns over its operational viability. The settlement not only removes a major financial overhang but also enhances Novavax’s appeal as a business partner, according to CEO John Jacobs. Settlement Terms Under the terms of the settlement, Novavax has made an upfront payment of $75 million to Gavi, with additional payments of $80 million annually in quarterly installments scheduled through 2028. These payments can be adjusted if Gavi opts to receive vaccines instead of cash. The agreement also includes provisions for extra vaccine credits, potentially worth up to $225 million, should demand exceed the annual $80 million mark. Strategic Implications For Novavax The resolution of this dispute is pivotal for Novavax, offering a path to stabilize its financials and focus on future endeavors. CEO John Jacobs highlighted the settlement’s role in mitigating the risk of a substantial one-time payment and enabling better cash flow management. The estimated present value of the settlement ranges between $300 and $400 million, signaling a strategic financial recalibration for the company. Looking Ahead With new leadership at the helm of both Novavax and Gavi, this agreement signals a fresh start and a mutual focus on future collaborations and initiatives. Novavax is already eyeing new revenue streams, with plans to introduce a combination COVID-flu vaccine by 2026 and capitalize on a malaria vaccine developed in partnership with the Serum Institute of India. These initiatives, coupled with significant cost reductions and operational streamlining, underscore Novavax’s commitment to overcoming past challenges and seizing future opportunities. Conclusion In conclusion, the settlement between Novavax and Gavi not only resolves a major dispute but also highlights the resilience and strategic pivoting of Novavax amidst the complexities of the global vaccine landscape. As the company navigates beyond its COVID-centric phase, this development offers promising insights into its potential for innovation, growth, and partnerships in the years to come.
NASDAQ:NVAXLong
by realchartchamp
NVAX rises impending an earnings report LONGToday NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings is coming this upcoming week. This week NVAX news release showed it had settled a years long litigation over a failed COVID. In the face of earnings around the corner, was this news release a coincidence or instead a case of excellent executive and legal timing? I will skip the conspiracy discussion. On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock that has been stuck in deeply undervalued territory for a significant time period is remarkable. I have bought far out of the money call options into 2025 and 2026 some only this past month. Those from this month are now up over 250% with 11 and 23 months to go to expiration. I see NVAX as a risky penny medical stock with a high reward potential relative to the risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out the competition when there is an opportunity and do not worry about the government crying monopoly when life-saving and life-extending medical products are involved. Time will tell. I expect insane profits.
NASDAQ:NVAX
by AwesomeAvani
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area of the volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing position here and again the next time I see a dip on the 15-30-minute chart. I look forward to take a piece out of the position after the next earnings report in about 75 days. I have an alert for relative volume when the running mean is exceeded on the 30 minute chart which notify me to take a look at the chart. This is illustrated on this longer time frame chart about the days around earnings but occurs from time to time from other events. As an aside, if NVAX gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be the leading candidate to do a takeover, friendly or otherwise.
NASDAQ:MRNALong
by AwesomeAvani
NVAX- a medical penny stock Buy Weakness LONGNVAX on a 120 minute chart demonstrates a trend down in the past month after a period of consolidation producing the POC line on the volume profile. The MACD shows some bullish divergence. The volume profile has high volume nodes at 4.0 and 5.0 separated by a relative volume void. NVAX fell quickly through that void. It can just as easily rise through it. See the linked article on NVA from TipRanks. Options volume and pricing analysis is that bets are looking at5.0 diligently. Fundamentally, NVAX has been range limited by its focus on COVID but it does have other projects in its pipeline admittedly on various timelines with varying probabilities of capitalizing on them depending on clinical trials FDA approvals and so on. On the imbedded relative strength table as compared with SPY and peers in the pharmaceutical, biotechnology, medical device and healthcare spaces NVAX compares favorably with MRNA its closest peer but is weak compared with most of the others I have selected especially with LLY, which is high-flying from its anti-obesity drug breakout. Device companies Stryker and Intuitive Surgical are quite strong as well. United Healthcare is dominant in the insurance subsector and strong overall. One often effective strategy is to buy when an instrument is oversold and undervalued at a discount. I will buy NVAX here no matter that I have insider connections with one of those medical device companies and a few not on the list. Sentiment only goes so far. I found the article compelling and so Novavax long I go. On a trading site left unsaid my screenname is "Bottom Feeding Grinder". I have an appetite for NVAX found at the bottom right now. This is a reversal/reversion to the mean long trade. It is not without risk. As a penny stock with high volumes, low cost of entry and perhaps low floats, volatility is underscored and exaggerated if a volume inflow gets underway That said, a short squeeze is within the spectrum of possibilities. Enough said for now.
NASDAQ:NVAXLong
by AwesomeAvani
Novavax- NVAX- Medical Technology Vaccine Focused LONGNVAX on the 15 minute chart has been compressing price action volatility into a symmetrical triangle. It in now in a breakout of the triangle and in the process when from undervalued on Monday to the upper trendline and then down to the support trendline and then up again. It passed through the volume profile and its high volume area. In short, it has bullish momentum capped off with a breakout from the high volume area into a bullflag to rest the weekend. I am in this stock going and now is an opportunity to add to the position. If a trader wants to know what I consider to be targets upside, let me know. Medical technology is expected to be among the hottest of subsectors for 2024. NVAX has been beaten down. I believe it has significant upside for the long term. in the short term, earnings are expected on February 28th so this is a trade to consider on that run up. Call options for March 2 or March 16 can be considered.
NASDAQ:NVAX
by AwesomeAvani
Nutrix Therapeutics ( NRIX) has momentum for earnings LONGNRIX , on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. It printed a "big ass" green engulfing candle to finish the week. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, price fell about 25% in 2023. earnings have been both line beats but the negative cash flow remains as a challenge. The volume and volatility show both are heightened in the pre-earnings run- up. . This is a risky earnings play, NRIX does not yet make money like many other young biotechnology companies trying to grow However, because it lost less than forecasted, buyer interest has increased. There is an absence of any options volume and so illiquidity prevents consideration of options trading. I suspect a long trade in shares may gain to $14 targeting the pivot highs of April 23 and November 22 for projected gain upside of about 65% ( stop loss of 2.5%) If earnings disappoint trader expectations and price fades I will stop out with a loss of about 2.5% This makes this long swing trade a projected 2.5 /65 a R:r of 25 which validates it as a conservative trade if taking only 5% or less of buyer power applied to the risk. Biotechnology is expected to be one of the hottest subsectors of 2024. This could be one of them.
NASDAQ:NVAXLong
by AwesomeAvani
CARA a Biotech Pennys Stock with earnings coming LONGCARA is here on a 15 minute chart. The earnings report is due March 4th. The price action is already demonstrative of bullish momentum. CARA rose 60% this past week. It is still on sale at 95% off its all time high. Spiking buying volume, and so an upgoing Price Vulme Trend and squeeze release triggers on lower time frames all have CARA moving well prior to earnings. I see this as a long trade setup quite well. The available option contract on a thin-chain for strike 2.5 on March 15 added 20% on Friday. I will pass on any options contracts as the thin volume is a higher-than-acceptable risk. I will be more than happy with another 60% price rise in the upcoming week and it could be more.
NASDAQ:CARALong
by AwesomeAvani
RZLT Biotechnology Penny Stock Reports in the next day LONGRZLT is a biotechnology company which has products in clinical development. Many are aware that means rigorous clinical trials before an FDA approval and a product line that generates earnings. Stock price is more about growth and potential more than anything else. That said the chart looks good and I sense there is momentum heading into earnings in the next day so this is a buy for me. I can see that price broke above a recent supply/resistance zone. This penny stock likely cannot be shorted so there is no selling pressure to be exerted until present longs have found their target. This can add to the momentum without the drag of that short selling. A penny here and a penny there it all adds up over time especially with compounding in active trading with penny stocks that have great range.
NASDAQ:RZLTLong
by AwesomeAvani
2
ROIV - BioTech reporting 2/13 as a LONG earnings tradeRoivant Scientes, on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, ROIV gained 38% in 2023 but has been down 4 %YTD. The volume and volatility show both are heightened in the pre-earnings run- up. The last report in November was a double beat which is good prognosis for the one upcomings. This is a risky earnings play, ROIV does not yet make money. However, because it lost less than forecasted, buyer interest has increased. The call option for 2/16 for a strike of $12.50 is priced at $ 5.00 per contract. I suspect a long trade in shares may gain to $ 11.50 targeting the double top at the turn of the year for a projected gain upside of about 7% (with a stop loss of 2.5%). Considering that ROIV has gained 12% this past week, 7% in the next two days is about the same trend angle. As to the call contract, I have considered 100% return as my expections for the two days before the earnings. If earnings disappoint trader expectations and price fades I will sell to close the contract. If earnings is as expected, I will roll the contract forward into the March monthly and add a bit more capital into the trade.
NASDAQ:ROIVLong
by AwesomeAvani
1
NVAX Novavax Options Ahead of EarningsIf you haven`t bought NVAX during the Covid Pandemic: Then analyzing the options chain and the chart patterns of NVAX Novavax prior to the earnings report this week, I would consider purchasing the 7.50usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $0.87. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NASDAQ:NVAXLong
by TopgOptions
4
NVAX Novavax Vaccine approved! Buy Opportunity!If you haven`t bought NVAX during the pandemic: Then you need to know that NVAX Novavax's recent achievements in gaining full marketing authorization for its COVID-19 vaccine, Nuvaxovid, in the UK and Singapore, alongside its availability in major U.S. pharmacies, have ignited optimism among investors. These milestones signify a bright future for NVAT stock. The international authorization of Nuvaxovid opens doors to vast markets, enhancing revenue potential and global recognition for Novavax. the EU delayed the approval, but will update its decision by the end of this month. Nuvaxovid's availability at CVS and Rite Aid in the U.S. immediately after regulatory clearance demonstrates its acceptance and accessibility. Nuvaxovid is a protein-based COVID-19 vaccine, different from the mRNA vaccines of PFE and MRNA. My price target is $10 by the end of this month. Looking forward to read your opinion about it.
NASDAQ:NVAXLong
by TopgOptions
$NVAX Trending Back Down to the Buy ZoneNVAX has started distributing millions of COVID-19 vaccine shots. However, NVAX is trending back down towards the buy zone. I think that this will present a great second chance buy opportunity after NVAX's recent rally to $8. The markets have been affected by the new Israel Palestine conflict. Other key events this week are September PPI inflation data and Fed meeting minutes on Wednesday October 11. I think the markets are likely to have some sideways price action on Tuesday in anticipation of the new inflation and fed data.
NASDAQ:NVAXLong
by realchartchamp
2